Securities Exchange Act

United States. Securities and Exchange Commission

Cytokinetics and Astellas Terminate Licensing Agreement for Skeletal Sarcomere Activators

Cytokinetics, Incorporated has filed a FORM 8-K (Current Report) with the Securities and Exchange Commission regarding the termination of its License and Collaboration Agreement with Astellas Pharma Inc., effective November 1, 2021. The agreement, which was signed on April 23, 2020, granted Astellas exclusive rights to co-develop and commercialize skeletal

United States. Securities and Exchange Commission

Cytokinetics Receives Orphan Drug Designation from FDA for CK-274 in the Treatment of Hypertrophic Cardiomyopathy

Cytokinetics, a late-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation to CK-274, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic hypertrophic cardiomyopathy (HCM). This designation provides Cytokinetics with benefits such as a seven-year period of U.S. marketing exclusivity